A Phase 1 Study of [225Ac]-FPI-1434 Injection

Official Title

A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours

Summary:

This is a first-in-human phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumour activity of [111In]-FPI-1547 Injection (radioimmuno-imaging agent) and [225Ac]-FPI-1434 Injection (radioimmuno-therapeutic) and to establish the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547. The study consists of a dose escalation portion, including both single and multi-dosing cohorts, of approximately five cohorts and a cold antibody sub-study portion of up to three cohorts.

Trial Description

Primary Outcome:

  • Dose Escalation: Incidence of adverse events (AEs).
  • Single-Dose Escalation: Incidence of dose limiting toxicities (DLTs).
  • Multi-Dose Escalation: Incidence of DLTs.
  • Dose Escalation: Incidence of clinically significant clinical laboratory abnormalities.
  • Dose Escalation: Changes in electrocardiogram (ECG) parameters (PR, QRS, QT, and QTc intervals).
  • Cold Antibody Sub-Study: Changes in uptake of [111In]-FPI-1547 Injection following FPI-1175 Infusion in selected regions of interest on SPECT/CT images.
  • Cold Antibody Sub-Study: Changes in radiation dose estimates for selected tissues, organs and whole body both for [111In]-FPI-1547 and [225Ac]-FPI-1434 Injection at various dose levels following FPI-1175 Infusion.
Secondary Outcome:
  • Dose Escalation and Cold Antibody Sub-Study: Tumour uptake of [111In]-FPI-1547 Injection in selected regions of interest on SPECT/CT images.
  • Dose Escalation: Radiation doses for selected organs and whole body both for [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.
  • Dose Escalation and Cold-Antibody Sub-Study: Radiation doses for tumour lesions for [225Ac]-FPI-1434 Injection.
  • Dose Escalation and Cold-Antibody Sub-Study: Clearance for radioactivity and for the targeting antibody.
  • Dose Escalation and Cold-Antibody Sub-Study: Area under the curve (AUC) for radioactivity and for the targeting antibody.
  • Dose Escalation and Cold-Antibody Sub-Study: Cmax for radioactivity and for the targeting antibody.
  • Dose Escalation and Cold-Antibody Sub-Study: Half-life for radioactivity and for the targeting antibody.
  • Dose Escalation and Cold-Antibody Sub-Study: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 or Prostate Cancer Working Group 3 (PCWG3) guidelines.
  • Dose Escalation: Changes in the corrected QT (QTc) interval in milliseconds after [225Ac]-FPI-1434 treatment, compared to baseline.
  • Dose Escalation and Cold-Antibody Sub-Study: Changes in human growth hormone (hGh) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.
  • Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor 1 (IGF-1) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.
  • Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor binding protein 3 (IGFBP-3) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection.
  • Cold Antibody Sub-Study: Incidence of AEs.
  • Cold Antibody Sub-Study: Incidence of clinically significant clinical laboratory abnormalities.
  • Cold Antibody Sub-Study: Changes in ECG parameters (PR, QRS, QT, and QTc intervals).
  • Dose Escalation and Cold-Antibody Sub-Study: Time to response (TTR).
  • Dose Escalation and Cold-Antibody Sub-Study: Duration of response (DoR).
  • Dose Escalation and Cold-Antibody Sub-Study: Progression free survival (PFS).
  • Dose Escalation and Cold-Antibody Sub-Study: Time to Progression (TTP).
  • Dose Escalation and Cold-Antibody Sub-Study: Disease control rate (DCR).
  • Dose Escalation and Cold-Antibody Sub-Study: Overall survival (OS).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society